Trials / Completed
CompletedNCT02340910
Dose-Response Effects of Whole Body Vibration on Spasticity and Walking in SCI
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Shepherd Center, Atlanta GA · Academic / Other
- Sex
- All
- Age
- 16 Years – 72 Years
- Healthy volunteers
- Not accepted
Summary
This study will enroll people with SCI who have spasticity and some ability to walk. The goal is to understand if standing on a platform and receiving WBV results in decreased spasticity and improved walking ability. Published article is available (PMID: 29959653)
Detailed description
Phase 1 of this study has been successfully completed. The results of Phase 1 indicate that a single session of WBV lasting for a total of 6 minutes (delivered in eight 45-sec bouts) at a high-frequency (50Hz) was associated with the largest decrease in spasticity (as measured by the pendulum test). The goal for Phase 2 is to determine whether longer doses of WBV result in greater reductions in spasticity as well as improvements in walking ability. Two different doses of WBV, a short dose and a long dose, will be tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Short Duration | During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz. |
| PROCEDURE | Long Duration | During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz. Interventions will occur for a total of 20 sessions over 4 consecutive weeks . |
Timeline
- Start date
- 2015-02-02
- Primary completion
- 2020-03-06
- Completion
- 2020-03-06
- First posted
- 2015-01-19
- Last updated
- 2021-03-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02340910. Inclusion in this directory is not an endorsement.